[ad_1]
The Covid vaccine developed in collaboration with the biotechnology company AstraZeneca and the University of Oxford is “effective in 95%This was stated by Pascal Soriot, CEO of the pharmaceutical company, underlining a similar success rate to the prophylaxis produced by Pfizer, with which the vaccination campaign in Italy on health workers began on December 27, and the one produced by Moderna .
The Oxford proprietary formula has already been tested in the elderly population, proving effective among over 70, that is, those groups most exposed to complications from coronavirus infection.
Covid, Oxford vaccine to start in January in the UK
The green light for the inoculation of the product by the British anti-drug agency should arrive “before Thursday” December 31stwhile UK distribution should start as soon as January 4th.
Oxford and AstraZeneca vaccine: its characteristics
According to the manager, the Oxford vaccine, developed in collaboration with our country, “is capable of eliminating 100%” severe symptoms Covid-19, which often leads to patients being hospitalized for intensive care and resuscitation.
The vaccine produced by AstraZeneca and the University of Oxford is a “formula victorious“, Stressed the managing director Pascal Soriot. “So far we believe that the vaccine is also effective against the English variant of the virus, but we cannot be sure, so we will conduct tests.
Covid: why the AstraZeneca vaccine costs less
Compared to the vaccine produced by Pfizer and BioNTech, AstraZeneca’s has a strength in terms of logistics: it can be stored, transported and handled at higher temperatures. In fact, it requires cooling conditions between 2 he 8 degrees centigrade, way above -70° C requested by the competitor.
Thanks to this peculiarity, costs could be reduced, considering that the Cold chain it could be respected thanks to equipment already widely used for other types of vaccines.
In addition, AstraZeneca has agreed to distribute it at cost of production, i.e. 2.8 euros per dose. This is approximately one-tenth of the market price of Moderna and Pfizer. That is why it can be easily bought and used in the poorest countries.
[ad_2]
